Recent Advances in Retinal Drug Delivery
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".
Deadline for manuscript submissions: closed (10 December 2021) | Viewed by 22932
Special Issue Editor
Special Issue Information
Dear Colleagues,
Wise people say that good and bad are interlinked. Each shortcoming on one hand is a blessing on the other. This is nicely presented by the unique situation of the retina regarding drug availability. Being sequestered from the rest of the body in a small eyeball and further isolated via the blood ocular barrier (BOB) makes it difficult for drugs given systemically to cross the vascular network and reach retinal structures. Nonetheless, if a drug is injected into the eyeball, it can easily reach local therapeutic levels and be relatively retained in the eye for a sizable amount of time. Moreover, the systemic dose that reaches the rest of the body following intravitreal injection is minute, and therefore, many adverse events can be bypassed.
This Special Issue will address this unique situation and will encompass topics extending from the trivial question of why repeated injections are not an appropriate solution, to the practicalities of reducing annual injection rates and bypassing injections via other technologies. The field seems to explode with innovative ideas, technologies, and start-up sprouting. Our issue will reflect this and present the reader with a snapshot of today, with a glimpse to the foreseeable future.
Dr. Ron Neumann
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- retina
- drug delivery
- anti-VEGF
- anti-inflammatory
- macular edema
- retinal vascular diseases
- degenerative diseases
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.